Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/214888
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women with early-stage hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. In the SOLTI-1805 TOT-HER3 trial, a single HER3-DXd dose was administered to 98 patients across two parts: 78 patients received 6.4 mg/kg (Part A), and 44 received a lower 5.6 mg/kg dose (Part B). The CelTIL score, measuring tumor cellularity and infiltrating lymphocytes from baseline to day 21, was used to assess drug activity. Part A demonstrated increased CelTIL score after one dose of HER3-DXd. Here we report CelTIL score and safety for Part B. In addition, the exploratory analyses of part A involve a comprehensive study of gene expression, somatic mutations, copy-number segments, and DNA-based subtypes, while Part B focuses on validating gene expression. RNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6). DNA findings indicate that CelTIL response is significantly associated with TP53 mutations, proliferation, non-luminal signatures, and a distinct DNA-based subtype (DNADX cluster-3). Critically, low HER2DX ERBB2 mRNA, correlates with increased HER3-DXd activity, which is validated through in vivo patient-derived xenograft models. This study proposes chemosensitivity determinants, DNA-based subtype classification, and low ERBB2 expression as potential markers for HER3-DXd activity in HER2-negative breast cancer. Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and report outcomes for Part B of the trial using lower HER3-DXd dose in patients with HER2-negative breast cancer.
Matèries
Matèries (anglès)
Citació
Citació
BRASÓ MARISTANY, Fara, FERRERO CAFIERO, Juan manuel, FALATO, Claudette, MARTÍNEZ SÁEZ, Olga, CEJALVO, Juan miguel, MARGELÍ VILA, Mireia, TOLOSA, Pablo, SALVADOR BOFILL, Francisco javier, CRUZ, Josefina, GONZÁLEZ FARRÉ, Blanca, SANFELIU, Esther, ÒDENA, Andreu, SERRA, Violeta, PARDO, Francisco, LUNA BARRERA, Ana maría, ARUMI, Miriam, GUERRA, Juan antonio, VILLACAMPA, Guillermo, SÁNCHEZ BAYONA, Rodrigo, CIRUELOS, Eva, ESPINOSA BRAVO, Martín, IZARZUGAZA, Yann, GALVÁN, Patricia, MATITO, Judit, PERNAS, Sònia, VIDAL, Maria, SANTHANAGOPAL, Anu, SELLAMI, Dalila, ESKER, Stephen, FAN, Pang dian, SUTO, Fumitaka, VIVANCOS, Ana, PASCUAL, Tomás, PRAT, Aleix, OLIVEIRA, Mafalda. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. _Nature Communications_. 2024. Vol. 15, núm. 1. [consulta: 24 de gener de 2026]. ISSN: 2041-1723. [Disponible a: https://hdl.handle.net/2445/214888]